Cargando…
Ranibizumab and conbercept for treating wet age-related macular degeneration in China: A systematic review and meta-analysis
BACKGROUND: This study aimed to evaluate the therapeutic effects of ranibizumab and conbercept on wet age-related macular degeneration. METHODS: Randomized controlled trials comparing ranibizumab and conbercept in the treatment of wet age-related macular degeneration were searched in the PubMed, Med...
Autores principales: | Pengfei, Jiang, Hanyu, Tan, Qinghua, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9191391/ https://www.ncbi.nlm.nih.gov/pubmed/35049171 http://dx.doi.org/10.1097/MD.0000000000027774 |
Ejemplares similares
-
Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
por: Wang, Luping, et al.
Publicado: (2018) -
Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015) -
Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration
por: Chen, Rui, et al.
Publicado: (2020) -
Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis, Nikolaos, et al.
Publicado: (2016) -
Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
por: Wang, Zongyi, et al.
Publicado: (2020)